Pair Name	Usnic acid, Bleomycin
Phytochemical Name	Usnic acid
Anticancer drug Name	Bleomycin
Disease Info	[ICD-11: 2F94]	Ascitic tumor		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	Effect-enhancing and toxicity-reducing activity of usnic acid in ascitic tumor-bearing mice treated with bleomycin

Pair Name	AKBA, Cisplatin
Phytochemical	AKBA
Drug	Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	Acetyl-11-keto-beta-boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle arrest, apoptosis induction, and autophagy suppression via p21-dependent signaling pathway

Pair Name	Berbamine, Arcyriaflavin A
Phytochemical	Berbamine
Drug	Arcyriaflavin A
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	Our findings suggest that a novel combination therapy involving berbamine and ArcA could effectively eradicate glioblastoma stem-like cells.

Pair Name	Daurinoline, Sorafenib
Phytochemical	Daurinoline
Drug	Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	Our study provides insights into the molecular mechanisms underlying DS-induced inhibition of VM, which may facilitate the development of a novel clinical anti-HCC drug. Moreover, our findings suggest that the combination of DS and sorafenib constitutes a potential therapeutic strategy for HCC.

Pair Name	Dihydroberberine, Sunitinib
Phytochemical	Dihydroberberine
Drug	Sunitinib
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	DCS induced the expression of cell cycle signal molecules that are known to be affected by JNK and p38. The change of cell cycle, in turn, led to down-regulation of JNK and p38, and further reduced IL-1 secretion. Collectively, these findings highlight potential molecular mechanisms of DCS chemotherapeutic activity and suggest that DCS is an efficacious strategy in NSCLC therapy.

Pair Name	Honokiol, Rosiglitazone
Phytochemical	Honokiol
Drug	Rosiglitazone
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression

Pair Name	Patchouli alcohol, Vincristine
Phytochemical	Patchouli alcohol
Drug	Vincristine
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	Patchouli alcohol induces G0 /G1 cell cycle arrest and apoptosis in vincristine-resistant non-small cell lung cancer through ROS-mediated DNA damage

Pair Name	Shogaol, Fluorouracil
Phytochemical	Shogaol
Drug	Fluorouracil
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	Influence of 6-shogaol potentiated on 5-fluorouracil treatment of liver cancer by promoting apoptosis and cell cycle arrest by regulating AKT/mTOR/MRP1 signalling

Pair Name	Ursolic acid, Cisplatin
Phytochemical	Ursolic acid
Drug	Cisplatin
Disease Info	[ICD-11: 2C77]	Cervical cancer		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	The combination of UA with DDP could more effectively inhibit SiHa cells proliferation and facilitate cell apoptosis through suppressing NF-κB p65.

Pair Name	Polyphyllin I, Palbociclib
Phytochemical	Polyphyllin I
Drug	Palbociclib
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Regulate Info	Down-regulation	G1/S-specific cyclin-E1		Expression
Result	We first time demonstrated PPI can disturb CDK2 function through upregulation of p21. The PPI effect on CDK2 provides a choice for a chemotherapeutic strategy for the elimination of NSCLC. Our study highlighted the clinical significance of simultaneously blocking of CDK2 and CDK4/6 for NSCLC treatment.